The stock of Zevra Therapeutics Inc (ZVRA) has seen a 10.43% increase in the past week, with a 19.20% gain in the past month, and a 8.61% flourish in the past quarter. The volatility ratio for the week is 4.95%, and the volatility levels for the past 30 days are at 5.42% for ZVRA. The simple moving average for the last 20 days is 3.97% for ZVRA stock, with a simple moving average of 39.55% for the last 200 days.
Is It Worth Investing in Zevra Therapeutics Inc (NASDAQ: ZVRA) Right Now?
The 36-month beta value for ZVRA is at 1.93. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZVRA is 52.30M, and currently, shorts hold a 9.56% of that float. The average trading volume for ZVRA on November 01, 2024 was 1.06M shares.
ZVRA) stock’s latest price update
Zevra Therapeutics Inc (NASDAQ: ZVRA)’s stock price has increased by 5.01 compared to its previous closing price of 8.15. However, the company has seen a 10.43% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-31 that CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024.
Analysts’ Opinion of ZVRA
Many brokerage firms have already submitted their reports for ZVRA stocks, with Guggenheim repeating the rating for ZVRA by listing it as a “Buy.” The predicted price for ZVRA in the upcoming period, according to Guggenheim is $20 based on the research report published on October 07, 2024 of the current year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ZVRA reach a price target of $25, previously predicting the price at $18. The rating they have provided for ZVRA stocks is “Buy” according to the report published on September 24th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to ZVRA, setting the target price at $17 in the report published on September 24th of the current year.
ZVRA Trading at 10.62% from the 50-Day Moving Average
After a stumble in the market that brought ZVRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.37% of loss for the given period.
Volatility was left at 5.42%, however, over the last 30 days, the volatility rate increased by 4.95%, as shares surge +20.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.01% upper at present.
During the last 5 trading sessions, ZVRA rose by +11.48%, which changed the moving average for the period of 200-days by +50.00% in comparison to the 20-day moving average, which settled at $8.24. In addition, Zevra Therapeutics Inc saw 30.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZVRA starting from Watton Corey Michael, who purchase 500 shares at the price of $7.92 back on Oct 11 ’24. After this action, Watton Corey Michael now owns 1,500 shares of Zevra Therapeutics Inc, valued at $3,958 using the latest closing price.
Clifton R. LaDuane, the CFO & Treasurer of Zevra Therapeutics Inc, purchase 2,000 shares at $6.77 during a trade that took place back on Jul 17 ’24, which means that Clifton R. LaDuane is holding 18,469 shares at $13,540 based on the most recent closing price.
Stock Fundamentals for ZVRA
Current profitability levels for the company are sitting at:
- -3.1 for the present operating margin
- 0.46 for the gross margin
The net margin for Zevra Therapeutics Inc stands at -2.74. The total capital return value is set at -0.65. Equity return is now at value -130.22, with -52.61 for asset returns.
Based on Zevra Therapeutics Inc (ZVRA), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.95. The debt to equity ratio resting at 1.81. The interest coverage ratio of the stock is -18.73.
Currently, EBITDA for the company is -48.6 million with net debt to EBITDA at -0.29. When we switch over and look at the enterprise to sales, we see a ratio of 19.58. The receivables turnover for the company is 2.68for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
In conclusion, Zevra Therapeutics Inc (ZVRA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
